See more : Ceejay Finance Limited (CEEJAY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cipla Limited (CIPLA.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cipla Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Sulja Bros Building Supplies Ltd. (SLJB) Income Statement Analysis – Financial Results
- Nan Juen International Co., Ltd. (6584.TWO) Income Statement Analysis – Financial Results
- CURO Group Holdings Corp. (CURO) Income Statement Analysis – Financial Results
- Warom Technology Incorporated Company (603855.SS) Income Statement Analysis – Financial Results
- Lingkaran Trans Kota Holdings Bhd (6645.KL) Income Statement Analysis – Financial Results
Cipla Limited (CIPLA.BO)
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 257.74B | 224.73B | 216.23B | 189.89B | 166.95B | 159.71B | 146.87B | 140.45B | 132.99B | 112.65B | 101.73B | 82.79B | 70.21B | 1.44B | 53.60B | 49.61B | 40.10B | 34.38B | 28.91B | 21.81B | 18.42B |
| Cost of Revenue | 90.44B | 89.61B | 92.30B | 80.20B | 66.09B | 63.61B | 60.54B | 58.91B | 55.90B | 45.82B | 42.14B | 32.66B | 30.34B | 31.26B | 24.53B | 25.70B | 22.48B | 18.99B | 15.71B | 12.25B | 10.99B |
| Gross Profit | 167.30B | 135.13B | 123.94B | 109.68B | 100.85B | 96.10B | 86.33B | 81.54B | 77.09B | 66.82B | 59.60B | 50.14B | 39.87B | -29.82B | 29.07B | 23.91B | 17.62B | 15.39B | 13.20B | 9.56B | 7.43B |
| Gross Profit Ratio | 64.91% | 60.13% | 57.32% | 57.76% | 60.41% | 60.17% | 58.78% | 58.05% | 57.97% | 59.32% | 58.58% | 60.55% | 56.79% | -2,070.43% | 54.23% | 48.19% | 43.93% | 44.77% | 45.66% | 43.84% | 40.33% |
| Research & Development | 4.30B | 3.85B | 2.66B | 1.33B | 3.55B | 3.57B | 2.69B | 2.80B | 2.19B | 1.12B | 1.06B | 432.10M | 363.00M | 264.70M | 2.51B | 2.36B | 2.05B | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 10.59B | 9.28B | 8.12B | 7.05B | 7.82B | 5.79B | 5.26B | 4.51B | 3.65B | 3.19B | 2.66B | 2.44B | 2.13B | 1.49B | 12.69B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 17.25B | 16.94B | 16.70B | 12.99B | 12.52B | 12.81B | 10.83B | 10.09B | 8.19B | 7.39B | 6.80B | 4.66B | 4.68B | 3.87B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.90B | 26.22B | 24.82B | 20.04B | 20.34B | 18.60B | 16.09B | 14.60B | 11.84B | 10.58B | 9.46B | 7.11B | 6.80B | 5.36B | 12.69B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -1.13B | 477.50M | 538.60M | 338.10M | 293.50M | 347.50M | 1.16B | 152.20M | 130.40M | 150.70M | 240.30M | 287.70M | 251.80M | 439.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 59.22B | 94.95B | 88.23B | 77.17B | 79.75B | 75.75B | 67.48B | 65.10B | 59.71B | 50.18B | 39.09B | 31.44B | 25.00B | 20.11B | 16.53B | 14.61B | 9.24B | 7.32B | 6.00B | 4.34B | 3.29B |
| Cost & Expenses | 149.66B | 184.55B | 180.53B | 157.38B | 145.84B | 139.36B | 128.02B | 124.01B | 115.60B | 96.00B | 81.23B | 64.10B | 55.34B | 51.36B | 41.05B | 40.31B | 31.72B | 26.31B | 21.72B | 16.59B | 14.28B |
| Interest Income | 2.08B | 1.62B | 796.20M | 472.60M | 676.70M | 598.60M | 296.40M | 124.80M | 98.50M | 98.10M | 171.10M | 44.10M | 84.10M | 71.30M | 0.00 | 192.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 711.30M | 1.08B | 1.05B | 1.53B | 1.89B | 1.64B | 1.09B | 1.57B | 1.16B | 712.70M | 557.10M | 275.70M | 238.40M | 173.20M | 229.50M | 522.30M | 0.00 | 69.50M | 114.20M | 0.00 | 0.00 |
| Depreciation & Amortization | 9.42B | 10.18B | 9.88B | 10.01B | 10.97B | 10.96B | 9.50B | 8.71B | 7.54B | 5.05B | 3.73B | 3.30B | 3.12B | 2.73B | 1.90B | 1.71B | 1.31B | 1.03B | 801.80M | 550.50M | 402.84M |
| EBITDA | 67.20B | 51.32B | 45.72B | 44.36B | 34.65B | 33.43B | 27.41B | 22.58B | 25.98B | 23.27B | 23.98B | 24.60B | 17.98B | 14.34B | 15.16B | 11.00B | 9.69B | 9.11B | 8.02B | 5.77B | 4.55B |
| EBITDA Ratio | 26.07% | 23.63% | 21.80% | 23.06% | 20.83% | 22.09% | 22.95% | 21.08% | 18.96% | 19.19% | 22.59% | 29.08% | 25.38% | 1,001.40% | 26.94% | 22.18% | 24.15% | 26.50% | 27.74% | 26.47% | 24.69% |
| Operating Income | 105.71B | 40.61B | 36.18B | 32.05B | 19.12B | 18.90B | 17.78B | 15.21B | 17.46B | 16.57B | 19.25B | 20.77B | 14.70B | 11.69B | 12.54B | 9.30B | 8.38B | 8.08B | 7.22B | 5.22B | 4.14B |
| Operating Income Ratio | 41.01% | 18.07% | 16.73% | 16.88% | 11.45% | 11.83% | 12.10% | 10.83% | 13.13% | 14.71% | 18.92% | 25.09% | 20.94% | 811.60% | 23.40% | 18.74% | 20.90% | 23.49% | 24.97% | 23.94% | 22.50% |
| Total Other Income/Expenses | -48.69B | -46.64B | -45.92B | -40.63B | 676.60M | 440.00M | -2.16B | -4.21B | -115.30M | -99.80M | -1.70B | 180.00M | -387.90M | 61.55B | 720.50M | -342.60M | -64.30M | 3.50M | -99.40M | -76.30M | -103.94M |
| Income Before Tax | 57.02B | 40.38B | 34.93B | 32.90B | 21.78B | 20.79B | 16.69B | 12.22B | 17.27B | 16.54B | 18.80B | 20.95B | 14.48B | 11.62B | 13.26B | 8.96B | 8.38B | 8.08B | 7.10B | 5.15B | 4.04B |
| Income Before Tax Ratio | 22.12% | 17.97% | 16.16% | 17.33% | 13.05% | 13.02% | 11.37% | 8.70% | 12.99% | 14.69% | 18.48% | 25.31% | 20.62% | 807.23% | 24.74% | 18.05% | 20.90% | 23.49% | 24.55% | 23.59% | 21.93% |
| Income Tax Expense | 15.47B | 12.03B | 9.34B | 8.89B | 6.31B | 5.70B | 2.50B | 1.80B | 3.32B | 4.00B | 4.63B | 5.44B | 3.07B | 1.95B | 2.44B | 1.25B | 1.37B | 1.40B | 1.02B | -1.05B | 877.50M |
| Net Income | 41.22B | 28.02B | 25.17B | 24.05B | 15.47B | 15.28B | 14.11B | 10.06B | 13.60B | 11.81B | 13.88B | 15.45B | 11.44B | 9.90B | 10.83B | 7.71B | 7.01B | 6.68B | 6.08B | 4.10B | 3.07B |
| Net Income Ratio | 15.99% | 12.47% | 11.64% | 12.66% | 9.26% | 9.57% | 9.60% | 7.17% | 10.23% | 10.48% | 13.65% | 18.66% | 16.30% | 687.15% | 20.20% | 15.54% | 17.48% | 19.42% | 21.02% | 18.78% | 16.65% |
| EPS | 51.05 | 34.72 | 31.20 | 29.82 | 19.19 | 18.97 | 17.53 | 12.52 | 16.93 | 14.71 | 17.29 | 19.24 | 14.25 | 12.32 | 13.70 | 9.92 | 9.02 | 8.61 | 8.10 | 5.46 | 3.94 |
| EPS Diluted | 51.01 | 34.69 | 31.17 | 29.79 | 19.16 | 18.93 | 17.50 | 12.50 | 16.89 | 14.66 | 17.27 | 19.24 | 14.25 | 12.32 | 13.70 | 9.92 | 9.02 | 8.61 | 8.10 | 5.46 | 3.94 |
| Weighted Avg Shares Out | 807.36M | 807.01M | 806.67M | 806.36M | 806.02M | 805.36M | 804.77M | 803.98M | 803.14M | 802.93M | 802.92M | 802.92M | 802.92M | 802.92M | 790.14M | 777.29M | 778.29M | 777.29M | 775.93M | 749.68M | 749.65M |
| Weighted Avg Shares Out (Dil) | 808.00M | 807.63M | 807.44M | 807.30M | 807.08M | 806.83M | 806.08M | 805.32M | 805.42M | 805.59M | 804.08M | 802.92M | 802.92M | 802.92M | 790.14M | 777.29M | 778.29M | 777.29M | 775.93M | 749.68M | 749.65M |
Source: https://incomestatements.info
Category: Stock Reports